Corporate & Investor Presentation
Why invest? - driving long-term shareholder value
0000
Market Dynamics
Growth & Innovation
Financial Results
• Underpenetrated markets in
sleep and COPD
• Healthcare costs continue to
increase
• Focus on improving patient
outcomes
• Value-based technology
solutions
• Global leader in digital health
for sleep and respiratory care
• Long-term growth
opportunities
•6,500+ patents and designs
•~7-8% of revenue invested in
R&D
• Historical revenue and profit
growth
• Recurring revenue
• Operating excellence program
• Strong track record of
disciplined capital deployment
Total Shareholder Return (NYSE shares as of 12/31/2020):
1-yr 38%
3-yr 160%
5-yr 327%
5 2021 ResMed | Corporate & Investor Presentation - updated 28JAN21
ResMedView entire presentation